###begin article-title 0
###xml 116 120 <span type="species:ncbi:10090">Mice</span>
###xml 136 141 <span type="species:ncbi:9606">Human</span>
Genetically-Defined Deficiency of Mannose-Binding Lectin Is Associated with Protection after Experimental Stroke in Mice and Outcome in Human Stroke
###end article-title 0
###begin p 1
Conceived and designed the experiments: AC AMP FL AC. Performed the experiments: AC AMP CJ XU JCJ. Analyzed the data: AC AMP FT FL AC. Contributed reagents/materials/analysis tools: JCJ. Wrote the paper: AC AMP AC.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 375 379 <span type="species:ncbi:10090">mice</span>
###xml 384 390 <span type="species:ncbi:9606">humans</span>
The complement system is a major effector of innate immunity that has been involved in stroke brain damage. Complement activation occurs through the classical, alternative and lectin pathways. The latter is initiated by mannose-binding lectin (MBL) and MBL-associated serine proteases (MASPs). Here we investigated whether the lectin pathway contributes to stroke outcome in mice and humans.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 184 188 <span type="species:ncbi:10090">mice</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 252 257 <span type="species:ncbi:9606">human</span>
###xml 492 500 <span type="species:ncbi:9606">patients</span>
Focal cerebral ischemia/reperfusion in MBL-null mice induced smaller infarctions, better functional outcome, and diminished C3 deposition and neutrophil infiltration than in wild-type mice. Accordingly, reconstitution of MBL-null mice with recombinant human MBL (rhMBL) enhanced brain damage. In order to investigate the clinical relevance of these experimental observations, a study of MBL2 and MASP-2 gene polymorphism rendering the lectin pathway dysfunctional was performed in 135 stroke patients. In logistic regression adjusted for age, gender and initial stroke severity, unfavourable outcome at 3 months was associated with MBL-sufficient genotype (OR 10.85, p = 0.008) and circulating MBL levels (OR 1.29, p = 0.04). Individuals carrying MBL-low genotypes (17.8%) had lower C3, C4, and CRP levels, and the proinflammatory cytokine profile was attenuated versus MBL-sufficient genotypes.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 117 123 <span type="species:ncbi:9606">humans</span>
In conclusion, genetically defined MBL-deficiency is associated with a better outcome after acute stroke in mice and humans.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 301 304 301 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Carroll1">[1]</xref>
###xml 714 717 714 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-vanBeek1">[2]</xref>
###xml 851 854 851 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Mocco1">[3]</xref>
###xml 856 859 856 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Lindsberg1">[4]</xref>
###xml 824 832 <span type="species:ncbi:9606">patients</span>
Innate immunity presents the first line of defense against infections through the recognition of pathogen-associated molecular patterns. Innate immunity also recognizes molecular motifs expressed by stressed or dead host cells following a general system of response referred to as innate autoimmunity [1]. The complement system is one of the major effector mechanisms of the innate immunity and its activation contributes to the release of inflammatory mediators, opsonophagocytosis and killing of pathogens and removal of damaged host cells. The complement system is activated after acute brain injury, and astrocytes, microglia, neurons, and oligodendrocytes are able to synthesize several complement components [2]. Recently, some clinical studies have provided evidence supporting activation of the complement system in patients with acute stroke [3], [4].
###end p 9
###begin p 10
###xml 259 262 259 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Frank1">[5]</xref>
###xml 407 410 407 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Mocco2">[6]</xref>
###xml 412 415 412 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-DeSimoni1">[7]</xref>
###xml 508 511 508 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Atkinson1">[8]</xref>
###xml 573 576 573 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Huang1">[9]</xref>
###xml 578 582 578 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Cowell1">[10]</xref>
###xml 672 676 672 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Ducruet1">[11]</xref>
###xml 756 761 <span type="species:ncbi:9606">human</span>
Crucial steps of the innate response entail the activation of the alternative pathway and the lectin pathway of the complement system, to converge in the generation of enzyme complexes that are able to cleave C3, which is the most abundant complement protein [5]. In experimental stroke, the complement system is also activated through non classical pathways (either the alternative or the lectin pathways) [6], [7]. Complement activation appears to contribute to the development of larger brain infarctions [8], hence depletion of complement results in beneficial effects [9], [10], more readily observed in situations where the brain ischemia is followed by reperfusion [11]. However, the mechanism and the clinical relevance of complement activation in human stroke remains unsettled.
###end p 10
###begin p 11
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Jordan1">[12]</xref>
###xml 322 326 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Hart1">[13]</xref>
###xml 360 364 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-deVries1">[14]</xref>
###xml 531 535 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Gesuete1">[15]</xref>
###xml 694 698 694 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Schwaeble1">[16]</xref>
###xml 822 826 822 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Dommett1">[17]</xref>
###xml 879 883 879 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Ogden1">[18]</xref>
###xml 436 442 <span type="species:ncbi:10090">murine</span>
Mannose-binding lectin (MBL) is a C-type collectin homologous to C1q that can initiate the activation of complement through the lectin pathway. This is an ancient and highly conserved pathway of complement activation that has been implicated in the pathophysiology of myocardial infarction [12], gastrointestinal ischemia [13], and kidney ischemia/reperfusion [14]. A recent study shows the benefits of C1 inhibitor administration in a murine model of cerebral ischemia/reperfusion and suggests that MBL is involved in this effect [15]. The activation of the lectin pathway is mediated by associated serine proteases, termed MASPs, since they were discovered as MBL-associated serine proteases [16]. Of those, MASP-2 is essential as it cleaves C4 and C2 components, leading to the formation of the classical C3 convertase [17]. MBL can also recognize and bind damaged host cells [18] and it is possible that this collectin might also recognize damaged cells in the central nervous system.
###end p 11
###begin p 12
###xml 198 202 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MBL2</italic>
###xml 208 212 208 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Dommett1">[17]</xref>
###xml 214 218 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Madsen1">[19]</xref>
###xml 233 238 233 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2</italic>
###xml 305 309 305 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-StengaardPedersen1">[20]</xref>
###xml 433 437 433 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MBL2</italic>
###xml 573 577 573 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Casanova1">[21]</xref>
###xml 702 712 702 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MBL2/MASP2</italic>
###xml 52 59 <span type="species:ncbi:9606">persons</span>
###xml 717 725 <span type="species:ncbi:9606">patients</span>
###xml 809 813 <span type="species:ncbi:10090">mice</span>
###xml 828 832 <span type="species:ncbi:10090">mice</span>
Low serum levels of MBL are reported in one in five persons of European descent due to the presence of single nucleotide polymorphisms (SNPs) in the promoter and the structural coding region of the MBL2 gene [17], [19]. A SNP in the MASP2 gene (D105>G) may also result in low circulating levels of MASP-2 [20] but little is known of its pathogenic consequences after experimental or clinical stroke. The worldwide expansion of a few MBL2 mutant alleles that lead to low serum levels of MBL has led to the suggestion that they might be advantageous under some circumstances [21]. In this study, we investigated the clinical implications of genetic polymorphisms of key components of the lectin pathway (MBL2/MASP2) in patients with acute stroke. We also assessed the consequences of acute ischemia in MBL-null mice and wild-type mice. To our knowledge, the results of this study underscore for the first time the central role of the lectin pathway of complement activation after acute stroke in clinical and experimental settings and illustrate that a richer expression of this soluble pattern recognition molecule in the innate immune system facilitates a stronger inflammatory response after acute brain injury.
###end p 12
###begin title 13
Materials and Methods
###end title 13
###begin title 14
###xml 18 22 <span type="species:ncbi:10090">Mice</span>
Brain Ischemia in Mice
###end title 14
###begin p 15
###xml 447 451 447 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Justicia1">[22]</xref>
###xml 747 751 747 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Clark1">[23]</xref>
###xml 1187 1194 1187 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008433.s001">Text S1</xref>
###xml 29 33 <span type="species:ncbi:10090">mice</span>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 308 312 <span type="species:ncbi:10090">Mice</span>
Four-month-old male MBL-null mice (B6.129S4-Mbl1tm1Kata Mbl2tm1Kata/J) were obtained from The Jackson's Laboratory. Age-matched male C57BL/6J wild-type (WT) mice were used as controls. Animal work was approved by the local Ethical Committee (Comite Etico de Experimentacion Animal, University of Barcelona). Mice were anesthetized with isoflurane and brain ischemia was induced by 2-hour occlusion of the middle cerebral artery (MCA), as reported [22]. Cortical perfusion was evaluated with laser Doppler flowmetry (Perimed, Sweden). Neurological deficits were assessed at 48 h. Infarct volume was measured at 48 h in 1 mm-thick coronal brain sections stained with 1% solution of 2,3,5- triphenyltetrazolium chloride (TTC). The area of infarction [23] (pale zone not turning red after staining) was measured in each section and a correction for oedema was made by multiplying the infarct area by the ratio of the contralateral to the ipsilateral hemisphere. The areas were integrated to calculate infarct volume. In each brain section, we calculated the percentage of hemispheric area that was infarcted by dividing the infarct area by the area of the contralateral hemisphere *100 (See Text S1).
###end p 15
###begin title 16
Reconstitution with rhMBL
###end title 16
###begin p 17
###xml 596 600 596 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Petersen1">[24]</xref>
###xml 740 744 732 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-MllerKristensen1">[25]</xref>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
An additional group of MBL-null mice received either endotoxin-free rhMBL or vehicle (tris-buffered saline, TBS). The rhMBL was generously supplied by NatImmune A/S, Copenhagen. It was produced by transfected HEK293F cells and purified by carbohydrate affinity chromatography and gel permeation chromatography. DNA was removed by Benzonase treatment; and several microfiltration and nanofiltration steps were done to reduce bioburden and elimination of adventitious virus. No sign of side effects such as would be expected from endotoxin contamination were seen in pre-clinical or phase I trials [24]. rhMBL (200 microg in 200 microl of TBS) or vehicle was given i.p. 4 times, i.e. 24 h, 14 h, and 2 h prior to MCA occlusion and 12 h later [25]. Researchers inducing ischemia and measuring infarct volume were not aware of the treatment assigned to each animal.
###end p 17
###begin title 18
Immunohistochemistry and Western Blotting
###end title 18
###begin p 19
###xml 516 517 516 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 800 804 800 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Justicia1">[22]</xref>
###xml 961 968 961 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008433.s001">Text S1</xref>
###xml 76 82 <span type="species:ncbi:9986">rabbit</span>
###xml 820 826 <span type="species:ncbi:9986">rabbit</span>
###xml 832 837 <span type="species:ncbi:10090">mouse</span>
Immunohistochemistry was performed in cryostat sections obtained at 48 h. A rabbit polyclonal antibody against C3 (Abcam, Cambridge, UK) was used diluted 1:500. The percent immunopositive area for each animal was measured using AnalySIS Software (Soft Imaging System). Quantification of C3 deposition was made in sections taken at three different coronal sections form Bregma +2 mm to Bregma -3 mm. Images were taken from 3 fields and the mean value was calculated for each animal. The area of each field was 0.32 mm2. Images were taken from the zones showing the highest intensity of fluorescence per each section. The sections were labeled with a code that did not reveal the identity of the animals. Brain protein extracts were obtained from frozen brain tissue and processed for Western blotting [22]. Two different rabbit anti-mouse antibodies against C3 (from Abcam and from Santa Cruz Biotechnology Inc., CA, USA) were used. Further details are given in Text S1.
###end p 19
###begin title 20
###xml 7 15 <span type="species:ncbi:9606">Patients</span>
Stroke Patients
###end title 20
###begin p 21
###xml 46 50 46 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Chamorro1">[26]</xref>
###xml 555 559 555 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Chamorro1">[26]</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients were part of the ESPIAS stroke trial [26]. Subjects gave specific written consent for genetic analyses. The study was conducted according to the Declaration of Helsinki principles and approved by an official Internal Review Board (Ethic Committee of Clinical Investigation of the Hospital Clinic of Barcelona; number of approval: HCP 01/01237). A modified Rankin Scale (MRS)<2, NIHSS score<2, and Barthel Index of 95 or 100 at 3 months indicated a favourable outcome. Another outcome measure was the incidence of infections during the first week [26].
###end p 21
###begin p 22
###xml 218 225 212 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008433.s001">Text S1</xref>
Blood was collected at baseline (day 0) and days 1, 2, 3, 4, 7, and 90, and serum was stored at -80degreesC. The concentration of leukocytes, C3 and C4, and of several cytokines and other molecules was quantified (see Text S1). The balance between T helper 1 (Th1) and Th2 cytokines was assessed by the relationship between circulating cytokine levels according to the calculation (TNF-alpha+IL-6)/IL-10.
###end p 22
###begin title 23
Genetic and Functional Assessment of the Lectin Pathway
###end title 23
###begin p 24
###xml 37 51 37 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MBL2 and MASP2</italic>
###xml 113 117 113 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Lozano1">[27]</xref>
###xml 123 130 123 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008433.s001">Text S1</xref>
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Madsen1">[19]</xref>
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Turner1">[28]</xref>
###xml 175 179 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Mullighan1">[29]</xref>
###xml 303 313 303 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2 gene</italic>
At day 0, genomic DNA was extracted. MBL2 and MASP2 were genotyped with reported sequence-based typing technique [27] (see Text S1). According to previous studies [19], [28], [29], genotypes 0/0, 0/XA, and XA/XA were classified as MBL-low variants while the remainders were MBL-sufficient variants. For MASP2 gene, SNP at codon 105 exon 3 implies a non-synonymous amino acid replacement (D105>G) at the CUB1 domain of MASP-2, which impedes association to MBL and significantly reduces MASP-2 levels.
###end p 24
###begin p 25
###xml 114 118 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Thiel1">[30]</xref>
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-MllerKristensen2">[31]</xref>
###xml 130 137 130 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008433.s001">Text S1</xref>
Serum concentrations (ng/ml) of MBL and MASP-2 were determined by time-resolved immunofluorometric assay (TRIFMA) [30], [31] (see Text S1).
###end p 25
###begin title 26
Statistical Analyses
###end title 26
###begin p 27
###xml 44 45 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
###xml 449 453 <span type="species:ncbi:10090">mice</span>
Categorical data were compared using the chi2 and Fisher's exact tests. Continuous variables were analyzed with the Student's t-test, non-parametric Mann-Whitney U-test, and Pearson or Spearman coefficients when required. ANCOVA adjusted for baseline values was used to assess serial changes of inflammatory parameters according to genotype. Two-way ANOVA was applied for comparisons of the percentage of infarcted area between MBL-null mice and WT mice for the different brain sections. Changes over time of MBL and MASP-2 levels were analysed with a longitudinal mixed model for repeated measurements that included genotype, time and their interaction in the model, and setting the type of covariance as unstructured. Logistic regression modeling was used to assess baseline predictors of functional independence at day 90 adjusted for the effects of age, gender and baseline NIHSS score.
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
MBL-Deficiency Is Beneficial in Experimental Brain Ischemia
###end title 29
###begin p 30
###xml 230 237 230 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g001">Fig. 1A</xref>
###xml 312 319 312 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g001">Fig. 1B</xref>
###xml 373 380 373 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g001">Fig. 1C</xref>
###xml 408 415 408 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g001">Fig. 1D</xref>
###xml 900 907 894 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g001">Fig. 1E</xref>
###xml 1276 1283 1270 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g001">Fig. 1F</xref>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 212 216 <span type="species:ncbi:10090">mice</span>
###xml 479 483 <span type="species:ncbi:10090">mice</span>
###xml 529 533 <span type="species:ncbi:10090">mice</span>
###xml 648 652 <span type="species:ncbi:10090">mice</span>
###xml 1027 1031 <span type="species:ncbi:10090">mice</span>
###xml 1243 1247 <span type="species:ncbi:10090">mice</span>
###xml 1259 1263 <span type="species:ncbi:10090">mice</span>
Brain damage after 2-hour middle cerebral artery occlusion (MCA) was assessed by measuring infarct volume at 48 h in WT (n = 10) and MBL-null (n = 11) mice. Representative images of infarction in WT and MBL-null mice are shown in Fig. 1A. Infarct volume was significantly reduced (p<0.05) in the MBL-null group (Fig. 1B). The effects were significant in cortical (p<0.05) (Fig. 1C) and subcortical (p<0.01) (Fig. 1D) structures. However, as the mean+/-SD body weight of MBL-null mice (26.50+/-0.46 g) was smaller than that of WT mice (29.05+/-0.93 g) (p<0.001), we made some calculations to reassure that the reduction in body size in the MBL-null mice did not contribute to the differences in infarct volume vs. WT. In each brain section, we calculated the percentage of hemispheric area that was infarcted by dividing the infarct area by the area of the contralateral hemisphere *100. The results (Fig. 1E) showed that the proportion of brain tissue that was infarcted in the different brain sections was smaller in MBL-null mice than in WT (p<0.001, two-way ANOVA by genotype and brain section). In agreement with the reduction in infarct size, the neurological test studied at 48 h showed that the functional deficit was minor in MBL-null mice than in WT mice (p = 0.05) (Fig. 1F).
###end p 30
###begin title 31
###xml 9 13 <span type="species:ncbi:10090">mice</span>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
MBL-null mice develop smaller infarct volumes than wild-type mice.
###end title 31
###begin p 32
###xml 1287 1288 1285 1286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
###xml 372 376 <span type="species:ncbi:10090">mice</span>
###xml 609 613 <span type="species:ncbi:10090">mice</span>
###xml 919 923 <span type="species:ncbi:10090">mice</span>
###xml 951 955 <span type="species:ncbi:10090">mice</span>
###xml 1046 1050 <span type="species:ncbi:10090">mice</span>
###xml 1119 1123 <span type="species:ncbi:10090">mice</span>
A) Representative images of infarcted brain tissue in wild-type (WT) and MBL-null mice at 48 h post-ischemia. The approximate level of the brain sections is indicated in the left by the distance from Bregma. B) Infarct volume was lesser in the MBL-null group (n = 11) than in WT (n = 10). C) Cortical and D) subcortical infarct volumes were smaller in MBL-null than in WT mice. E) The percentage of tissue with infarction per brain section (1 mm-thick) is shown for consecutive sections, starting (left) from the frontal part of the brain. The proportion of infarcted tissue is smaller in MBL-null than in WT mice. Values are expressed as the mean+/-SD. Two-way ANOVA by genotype and brain section showed significant differences due to genotype (p<0.001, F(9,40) = 18.74). Post-hoc Bonferroni test showed significant differences in the indicated brain sections. F) The neurological score was better (lower) in MBL-null mice than in WT. (G-H) MBL-null mice were treated with rhMBL (MBLnull+rhMBL) (n = 4) or vehicle (MBLnull) (n = 5). G) MBL-null mice receiving rhMBL showed larger infarct volume than non-reconstituted mice. H) A trend to worst neurological deficit (p = 0.09) was seen after reconstitution with rhMBL compared to vehicle. Symbols indicate values for individual animals. * p<0.05, ** p<0.01, *** p<0.001).
###end p 32
###begin p 33
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 464 468 <span type="species:ncbi:10090">mice</span>
###xml 680 684 <span type="species:ncbi:10090">mice</span>
The magnitude of the ischemic lesion is dependent on the reduction of cerebral blood flow (CBF) experimentally induced by occlusion of the middle cerebral artery (MCA). For this reason, we verified that MBL-deficient mice responded to MCA occlusion with a similar perfusion deficit than WT mice by monitoring CBF with laser Doppler flowmetry. The results showed that CBF (mean+/-SD) dropped until 30+/-8% and 32+/-7% of baseline in WT mice (n = 6) and in MBL-null mice (n = 8), respectively. The results illustrated that MBL-deficiency did not affect (p = 0.61) the CBF response to MCA occlusion and, thus, that the severity of the induced ischemia was similar in WT and MBL-null mice.
###end p 33
###begin p 34
###xml 332 336 332 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-MllerKristensen1">[25]</xref>
###xml 469 476 469 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g001">Fig. 1G</xref>
###xml 748 755 748 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g001">Fig. 1H</xref>
###xml 60 65 <span type="species:ncbi:9606">human</span>
###xml 110 114 <span type="species:ncbi:10090">mice</span>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
###xml 433 437 <span type="species:ncbi:10090">mice</span>
We then carried reconstitution experiments by administering human recombinant MBL (rhMBL) protein to MBL-null mice to validate that the smaller infarct volume in these animals was attributable to the lack of MBL. rhMBL or vehicle was administered i.p. following a reconstitution protocol that rescues MBL pathway activity in plasma [25]. MBL-null mice that were reconstituted with rhMBL showed a significantly larger infarction than mice of the vehicle group (p<0.05) (Fig. 1G), in spite that a similar CBF reduction after ischemia was observed after rhMBL or vehicle (p = 0.84). Also, a trend was observed for a worst neurological score in the rhMBL group, but the difference compared with vehicle did not reach statistic significance (p = 0.09) (Fig. 1H).
###end p 34
###begin title 35
###xml 63 67 <span type="species:ncbi:10090">Mice</span>
Post-Ischemic Complement Activation Was Attenuated in MBL-Null Mice vs. WT
###end title 35
###begin p 36
###xml 339 346 339 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g002">Fig. 2A</xref>
###xml 461 468 461 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g002">Fig. 2B</xref>
###xml 651 658 651 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g002">Fig. 2C</xref>
###xml 55 60 <span type="species:ncbi:10090">mouse</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
###xml 333 337 <span type="species:ncbi:10090">mice</span>
###xml 750 754 <span type="species:ncbi:10090">mice</span>
###xml 847 851 <span type="species:ncbi:10090">mice</span>
We examined the deposition of C3 complement protein in mouse brain by means of immunohistochemistry in frozen sections of brain tissue obtained at 48 h post-ischemia. C3 immunoreactivity was observed in blood vessels and also within the brain parenchyma in the ipsilateral hemisphere of WT mice, and, to a lesser extent, of MBL-null mice (Fig. 2A). Counterstaining the C3 immunoreaction with Hoechst showed C3 positive reaction surrounding certain cell bodies (Fig. 2B). For a quantitative assessment of differences in C3 immunoreactivity between groups we measured the C3-positive area in microscope images taken from the ischemic zone. The results (Fig. 2C) showed that the C3-immunoreactive area was smaller in MBL-null (n = 5) than in WT (n = 5) mice, thus supporting that the extent of complement activation was milder in MBL-null than in WT mice.
###end p 36
###begin title 37
###xml 87 91 <span type="species:ncbi:10090">mice</span>
Ischemia-induced C3 deposition in brain parenchyma is attenuated in MBL-null versus WT mice.
###end title 37
###begin p 38
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
###xml 634 638 <span type="species:ncbi:10090">mice</span>
A) C3 deposition (red), laminin immunostaining (blue), and CD11b (green). C3 immunoreaction is often associated to vessels and it is also found within the ischemic brain parenchyma. The C3 reaction is more moderate in MBL-null mice than in the WT. Control indicates non-operated WT mice. Bar scale  = 10 microm. B) C3 deposition (red) and Hoechst counterstaining to illustrate the cell nuclei shows C3 immunoreaction surrounding certain cell bodies (arrow in b). (b) is a magnification of the square shown in (a). C) Quantification of the C3 immunoreactive area in the ipsilateral hemisphere shows a significant reduction in MBL-null mice (n = 5) versus the WT (n = 5). Values are expressed as the mean+/-SD. Bar scale: (a) 100 microm, (b) 10 microm. * indicates p<0.05.
###end p 38
###begin p 39
###xml 646 653 627 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g003">Fig. 3A</xref>
###xml 758 771 739 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g003">Fig. 3A and B</xref>
###xml 955 968 936 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g003">Fig. 3C and D</xref>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 752 756 <span type="species:ncbi:10090">mice</span>
###xml 863 867 <span type="species:ncbi:10090">mice</span>
###xml 949 953 <span type="species:ncbi:10090">mice</span>
Native C3 is a heterodimeric protein made of one alpha-chain (115-kDa) and one beta-chain. C3 activation causes cleavage of C3alpha and generation of an active C3a fragment (9 kDa) and the remaining fragment named C3balpha'. The latter can covalently bind to small target proteins and acquire a greater apparent molecular mass. Evidence for C3 cleavage after brain ischemia was obtained by studying frozen brain tissue that was homogenized with detergent and examined by Western blotting using development with anti-C3 antibody. In the ischemic brain tissue of WT mice, the full length C3 protein and the C3alpha chain were degraded, as shown in Fig. 3A, suggesting cleavage of the protein. This effect occurred to a lesser extent in ischemic MBL-null mice (Fig. 3A and B). Moreover, we detected a C3 fragment of around 120 kDa in the ischemic brain tissue of WT mice, which was absent in the control brain, and less abundant in MBL-null than in WT mice (Fig. 3C and D). This protein had a molecular weight compatible with C3balpha'.
###end p 39
###begin title 40
###xml 93 97 <span type="species:ncbi:10090">mice</span>
C3 activation and neutrophil infiltration in the ischemic brain is lower in MBL-null than WT mice.
###end title 40
###begin p 41
###xml 55 61 <span type="species:ncbi:9986">rabbit</span>
###xml 67 72 <span type="species:ncbi:10090">mouse</span>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 163 167 <span type="species:ncbi:10090">mice</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
###xml 548 552 <span type="species:ncbi:10090">mice</span>
###xml 679 683 <span type="species:ncbi:10090">mice</span>
###xml 718 722 <span type="species:ncbi:10090">mice</span>
A) C3 alpha-chain is observed in control tissue with a rabbit anti-mouse C3 antibody. C3 is cleaved after ischemia in WT mice and, to a lesser extent, in MBL-null mice. Lanes represent different animals. B) Quantification of band optical density shows more severe cleavage of the C3 alpha-chain in WT than in MBL-null mice. C) The C3balpha' fragment (120 kDa) is evidenced in the ischemic tissue with an anti-C3 antibody. D) Quantification of band optical density shows that C3balpha' is more abundant in the ischemic tissue of WT than of MBL-null mice. E) Myeloperoxidase (MPO) is a marker of neutrophil infiltration in brain tissue. MPO is detected in the ischemic brain of WT mice, while it is attenuated in MBL-KO mice, as shown in F). Values are expressed as mean+/-SD. * p<0.05.
###end p 41
###begin p 42
###xml 290 303 290 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g003">Fig. 3E and F</xref>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
###xml 284 288 <span type="species:ncbi:10090">mice</span>
As an indicator of neutrophil accumulation in the ischemic brain, expression of myeloperoxidase (MPO) was assessed by Western blotting in frozen brain tissue using an anti-MPO antibody. Ischemia induced MPO accumulation in the brain of WT mice, and this effect was milder in MBL-null mice (Fig. 3E and F), suggesting that neutrophil accumulation after ischemia was attenuated in the brain of MBL-deficient animals.
###end p 42
###begin title 43
###xml 23 28 <span type="species:ncbi:9606">Human</span>
The Mannose-Pathway in Human Stroke
###end title 43
###begin p 44
###xml 672 680 672 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008433.s004">Table S1</xref>
###xml 948 952 948 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Chamorro1">[26]</xref>
###xml 147 152 <span type="species:ncbi:9606">human</span>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
###xml 368 376 <span type="species:ncbi:9606">patients</span>
###xml 473 481 <span type="species:ncbi:9606">Patients</span>
###xml 759 767 <span type="species:ncbi:9606">patients</span>
###xml 829 837 <span type="species:ncbi:9606">patients</span>
###xml 911 919 <span type="species:ncbi:9606">patients</span>
We undertook investigations to find out whether the neuroprotective effects of MBL-deficiency found in experimental brain ischemia are relevant to human stroke. For this purpose, we studied the genotype, and measured MBL levels, together with C3 and C4 complement proteins, and several markers of inflammation in the serum of our patients. One-hundred and thirty five patients completed the study, including 109 (80.7%) ischemic strokes and 26 (19.3%) hemorrhagic strokes. Patients with ischemic or hemorrhagic stroke disclosed no significant differences in demographics, risk factors, stroke severity on admission, clinical course, MBL and MAPS2 genotype and levels (see Table S1). Infections during the first 7 days after stroke were observed in 24 (17.8%) patients, functional independence at day 90 was reached by 47 (34.8%) patients, and there were 25 deaths at day 90 (19%). Other general traits of these patients were as previously reported [26].
###end p 44
###begin p 45
###xml 182 189 182 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g004">Fig. 4A</xref>
###xml 367 372 367 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2</italic>
###xml 509 513 509 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-StengaardPedersen1">[20]</xref>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Sorensen1">[32]</xref>
###xml 540 545 540 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2</italic>
###xml 601 608 601 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g004">Fig. 4B</xref>
###xml 832 836 832 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MBL2</italic>
###xml 840 845 840 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2</italic>
###xml 869 876 869 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008433-t001">Table 1</xref>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 314 322 <span type="species:ncbi:9606">patients</span>
###xml 397 405 <span type="species:ncbi:9606">patients</span>
###xml 521 529 <span type="species:ncbi:9606">Patients</span>
In our study, twenty-four (17.8%) patients had genetic MBL-low variants. These patients showed lower serum levels of MBL protein than the group with genetic MBL-sufficient variants (Fig. 4A). MBL levels in serum disclosed no major fluctuations over time after stroke onset (p = 0.79). In addition, fifteen (11.1%) patients were heterozygous for the D105>G SNP at the MASP2 gene, while none of the patients were homozygous. This SNP has been linked to a severe immunodeficiency when presented in homozygousity [20], [32]. Patients with this MASP2 polymorphism disclosed lower levels of MASP-2 protein (Fig. 4B). Overall, there were no significant changes in circulating levels of MASP-2 over time (p = 0.82). Demographics, risk factors, clinical parameters at admission, and treatment allocation were evenly distributed according to MBL2 or MASP2 genotypes, as shown in Table 1.
###end p 45
###begin title 46
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MBL2</italic>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2</italic>
Serum levels of MBL and MASP-2 and complement system activation according to MBL2 and MASP2 genotypes.
###end title 46
###begin p 47
###xml 169 174 169 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2</italic>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
A) Serum concentrations (ng/ml) of MBL in MBL-low genotypes and MBL-sufficient genotypes. B) Serum concentrations (ng/ml) of MASP-2 in patients with D105>G or wild-type MASP2 genotypes. Measurements were performed at day 0 (d0) (n = 96), day 1 (d1) (n = 10), day 2 (d2) (n = 7), day 3 (d3) (n = 10), day 4 (d4) (n = 10), day 7 (d7) (n = 9) and day 90 (d90) (n = 96). C) Serum concentration (g/L) of C3 and C4 at day 0 (d0) (n = 96) and day 2 (d2) (n = 96). Values are the mean +/-SD. *p<0.05; **p<0.01; ***p<0.0001.
###end p 47
###begin title 48
Baseline characteristics in the study population (n = 135) according to MBL and MASP2 genotype.
###end title 48
###begin p 49
###xml 119 126 119 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g004">Fig. 4C</xref>
###xml 384 389 384 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2</italic>
###xml 455 462 455 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008433.s002">Fig. S1</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Patients with MBL-low genotypes disclosed lower serum levels of C3 and C4 than patients with MBL-sufficient genotypes (Fig. 4C). Likewise, MBL levels were positively correlated with C3 at different time points after stroke onset, i.e. day 0 (r = 0.23, p = 0.01) and at day 2 (r = 0.34, p<0.01), and C4 at day 0 (r = 0.31, p<0.01), and at day 2 (r = 0.36, p = 0.001). In contrast, the MASP2 genotype did not influence the levels of C3 and C4 after stroke (Fig. S1).
###end p 49
###begin title 50
###xml 62 70 <span type="species:ncbi:9606">Patients</span>
Circulating C-Reactive Protein and Cytokine Profile of Stroke Patients According to Their Genotype
###end title 50
###begin p 51
###xml 94 101 94 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g005">Fig. 5A</xref>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2</italic>
###xml 303 310 303 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g005">Fig. 5B</xref>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
CRP levels were lower in patients with MBL-low genotypes compared to MBL-sufficient genotype (Fig. 5A), but were not related with the MASP2 genotype (data not shown). In exploratory analyses restricted to patients without infections, a lower rise of CRP was confirmed in patients with MBL-low variants (Fig. 5B). Expectedly, CRP and IL-6 were highly correlated (r = 0.37, p<0.0001). CRP was also positively correlated with C3 (r = 0.44, p<0.0001), and C4 (r = 0.33, p<0.01).
###end p 51
###begin title 52
C-reactive protein levels (mg/dL) in MBL-low genotypes and MBL-sufficient genotypes.
###end title 52
###begin p 53
###xml 7 15 <span type="species:ncbi:9606">patients</span>
###xml 438 446 <span type="species:ncbi:9606">Patients</span>
A) All patients, day 0 (d0) baseline (n = 127; MBL-low = 23, MBL-sufficient = 104); day 1 (d1) (n = 131; MBL-low = 24, MBL-sufficient = 107); day 2 (d2) (n = 132; MBL-low = 24, MBL-sufficient = 108); day 3 (d3) (n = 127; MBL-low = 24, MBL-sufficient = 103); day 4 (d4) (n = 122; MBL-low = 22, MBL-sufficient = 100), day 7 (d7) (n = 111; MBL-low = 19, MBL-sufficient = 92), and day 90 (d90) (n = 68; MBL-low = 12, MBL-sufficient = 56). B) Patients without post-stroke infections, d0 (n = 103; MBL-low = 18, MBL-sufficient = 85); d1 (n = 107; MBL-low = 19, MBL-sufficient = 88); d2 (n = 108; MBL-low = 19, MBL-sufficient = 89); d3 (n = 105; MBL-low = 19, MBL-sufficient = 86); d4 (n = 101; MBL-low = 17, MBL-sufficient = 84), d7 (n = 91; MBL-low = 15, MBL-sufficient = 76), and d90 (n = 60; MBL-low = 11, MBL-sufficient = 49). Values were obtained from serum and are expressed as the mean +/- SD. * p<0.05, ** p = 0.01. *p<0.05, **p = 0.01.
###end p 53
###begin p 54
###xml 216 225 212 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008433-g006">Fig. 6A&#8211;D</xref>
###xml 470 475 466 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2</italic>
###xml 479 483 475 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MBL2</italic>
###xml 8 16 <span type="species:ncbi:9606">patients</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
MBL-low patients showed a cytokine profile after stroke characterized by a greater increase of IL-10, a lower rise of IL-6, and no significant changes of TNF-alpha compared to patients with MBL-sufficient genotypes (Fig. 6A-D). This predominant anti-inflammatory cytokine response remained significant 3 months after stroke onset. The temporal course of other immune players, such as neutrophils, monocytes, and lymphocytes, did not show a significant effect related to MASP2 or MBL2 genotypes (data not shown).
###end p 54
###begin title 55
Cytokine levels (pg/ml) in blood in MBL-low genotypes and MBL-sufficient genotypes.
###end title 55
###begin p 56
A) Interleukin-10; B) Interleukin-6; C) TNF-alpha; D) Balance between T helper (h) 1 cytokines and Th2 cytokines calculated as (TNF-alpha + IL-6)/IL-10. Measurements were performed in serum samples at day 0 (d0) (n = 129; MBL-low = 23, MBL-sufficient = 106); day1 (d1) (n = 121; MBL-low = 22, MBL-sufficient = 99); day 2 (d2) (n = 122; MBL-low = 22, MBL-sufficient = 100); day 3 (d3) (n = 116; MBL-low = 19, MBL-sufficient = 97); day 4 (d4) (n = 111; MBL-low = 16, MBL-sufficient = 95), day 7 (d7) (n = 101; MBL-low = 16, MBL-sufficient = 85), and day 90 (d90) (n = 92; MBL-low = 15, MBL-sufficient = 77). Values are the mean +/- SD. *p<0.05, **p<0.01.
###end p 56
###begin title 57
###xml 19 27 <span type="species:ncbi:9606">Patients</span>
Stroke Recovery in Patients
###end title 57
###begin p 58
###xml 144 145 142 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 836 843 834 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008433.s003">Fig. S2</xref>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 743 751 <span type="species:ncbi:9606">patients</span>
Functional independence at day 90 was observed in 14 patients (58.3%) with MBL-low, and in 33 patients (29.7%) with MBL-sufficient genotype (chi2, p = 0.008). Unfavourable outcome at 3 months after stroke was associated with MBL-sufficient genotype (OR 10.85, 95% CI 62.94-1.87, p = 0.008) and MBL levels (OR 1.29, 95% CI 1.69-1.02, for every 500 units increase, p = 0.04) in a logistic regression model adjusted for age (OR 1.06, 95% CI 1.00-1.12, p = 0.04), sex (OR 0.32, 95% CI 0.09-1.16, versus male gender, p = 0.08), and initial stroke severity (OR 4.14, 95% CI 2.20-7.88, for each quartile of NIHSS score, p<0.0001). The MASP2-sufficient genotype (OR 0.92, 95% CI 0.23-3.73, p = 0.91) was not associated with stroke recovery. And last, patients with unfavourable outcome showed a predominantly pro-inflammatory cytokine profile (Fig. S2).
###end p 58
###begin p 59
###xml 149 150 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 177 182 175 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2</italic>
###xml 322 323 318 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 595 600 591 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2</italic>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 281 289 <span type="species:ncbi:9606">patients</span>
Post-stroke infections at day 7 were observed in 5 (20.8%) patients with MBL-low genotypes and 19 (17.1%) patients with MBL-sufficient genotypes (chi2, p = 0.67). Regarding the MASP2 genotype, post-stroke infections appeared in 2 (13.3%) patients with D105>G SNP and in 22 (18.3%) patients with the wild-type genotype (chi2, p = 0.63). The risk of infection after stroke was not associated with the serum levels of MBL at day 0 (p = 0.47) or at day 90 (p = 0.95), the levels of MASP-2 at day 0 (p = 0.07) or at day 90 (p = 0.14), the MBL genotype (OR = 1.27, 95% CI 0.42-3.84, p = 0.67), or the MASP2 genotype (OR = 0.68, 95% CI 0.14-3.25, p = 0.63).
###end p 59
###begin title 60
Discussion
###end title 60
###begin p 61
###xml 132 135 132 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Mocco1">[3]</xref>
###xml 137 140 137 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Lindsberg1">[4]</xref>
###xml 142 146 142 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Pedersen1">[33]</xref>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
###xml 324 330 <span type="species:ncbi:9606">humans</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
###xml 603 607 <span type="species:ncbi:10090">mice</span>
The complement is an integral component of the innate immune system that has been implicated in the pathophysiology of acute stroke [3], [4], [33]. In this study, we report for the first time the important contribution of the lectin pathway of complement activation to brain tissue fate after acute stroke, both in mice and humans. All the patients included in this study participated in a randomized, double-blind, controlled trial that limited the likelihood of clinical bias, and the main clinical findings of the study were in consonance with the results in experiments conducted in WT and MBL-null mice.
###end p 61
###begin p 62
###xml 498 502 498 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MBL2</italic>
###xml 1126 1130 1126 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Chamorro2">[34]</xref>
###xml 1294 1298 1294 1298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Gesuete1">[15]</xref>
###xml 9 13 <span type="species:ncbi:10090">mice</span>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 252 256 <span type="species:ncbi:10090">mice</span>
###xml 380 384 <span type="species:ncbi:10090">mice</span>
###xml 1251 1257 <span type="species:ncbi:10090">murine</span>
MBL-null mice disclosed after stroke smaller infarctions, and better functional outcome than WT mice. This effect was associated with attenuation of complement deposition and neutrophil accumulation into the ischemic brain tissue in MBL-null versus WT mice. The contribution of MBL to ischemic brain damage was further confirmed when MBL was exogenously reconstituted in MBL-null mice. In agreement with these findings in experimental animals, the main clinical contribution of this study was that MBL2 genotypes, which were associated with low circulating levels of functional MBL protein oligomers, increased approximately 11 times the odds of good functional outcome after stroke. Indeed, carriers of this genetic trait doubled the chance of becoming functionally independent stroke survivors, independently of the effects of established key prognostic factors such as age, gender, and initial stroke severity. Importantly, the benefits of a MBL-low genotype on stroke recovery were not counterbalanced by an increased risk of infections which have been recently associated with a stroke-induced immune-depression syndrome [34]. These results concur with a recent study suggesting that MBL is involved in the protective effect of C1 inhibitor in a murine model of brain ischemia/reperfusion [15].
###end p 62
###begin p 63
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2</italic>
###xml 381 385 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Sorensen1">[32]</xref>
###xml 448 453 448 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2</italic>
###xml 521 526 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MASP2</italic>
###xml 757 761 757 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-StengaardPedersen1">[20]</xref>
###xml 1017 1021 1017 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Shiratsuchi1">[35]</xref>
Unlike the major contribution of MBL, the study did not unravel a significant involvement of MASP2 genotype or MASP-2 levels in the prognosis of stroke. It has been speculated that MASP-2 deficiency might have broader consequences than MBL deficiency because MASP-2 is involved in the biological activity of not only MBL but also ficolins, a group of functionally related proteins [32]. However, we did not find an association between heterozygous MASP2 variant genotypes and stroke outcome. Since heterozygosity for the MASP2 variant allotypes does not lead to significant reduction in the function of the lectin pathway, it is likely that the D105>G variant is only relevant in homozygousity, which, with a gene frequency of about 5%, is a rare condition [20]. Nonetheless, on the basis of our findings we cannot fully exclude the possibility that MBL might have effects independent of MASP-2, as suggested by several findings. For instance, MBL stimulates macrophage phagocytosis in a manner independent of MASP-2 [35]. This matter deserves further investigation.
###end p 63
###begin p 64
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Chaka1">[36]</xref>
###xml 254 258 254 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MBL2</italic>
###xml 621 625 621 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Urra1">[37]</xref>
The inflammatory and lytic effects of complement may significantly contribute to tissue damage and MBL may modulate inflammation and trigger pro-inflammatory cytokine release from monocytes [36]. Although we found no significant associations between the MBL2 genotype and the total number of circulating monocytes or other white blood cells, we did not assess the phenotype of monocytes in this cohort. However, recent studies by our group have shown assorted effects of stroke on circulating monocytes including an early rise of minor subpopulations with less inflammatory drive and increased capacity for tissue repair [37]. Therefore, further investigation will be required to identify the phenotypic traits of monocytes of subjects with MBL-low genotypes.
###end p 64
###begin p 65
###xml 295 299 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Kaplan1">[38]</xref>
###xml 671 675 671 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-DiNapoli1">[39]</xref>
###xml 797 801 797 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Griselli1">[40]</xref>
###xml 812 816 812 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Gill1">[41]</xref>
The study identified that the individuals carrying MBL-low genotypes had lower peaks of CRP, C3 and C4 in serum, and a strong correlation between CRP, C3 and C4 complement proteins, in agreement with experiments indicating that the complement-activating functions of CRP and MBL are coordinated [38]. CRP is a classic acute phase reactant that belongs to the pentraxin family of calcium dependent ligand-binding plasma proteins that play a role in the humoral innate response. CRP binds with high affinity to phosphocholine residues and with a variety of autologous and extrinsic ligands which are more extensively exposed in or on damaged cells and tissues (reviewed in [39]). Animal studies have shown that CRP can enhance ischemic tissue damage by a complement-dependent mechanism in the heart [40] and brain [41]. The results of our study indicate that the deleterious effects of MBL after acute stroke are associated with increased concentrations of CRP, although additional studies will be required to determine whether there is a causal effect.
###end p 65
###begin p 66
###xml 582 586 582 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Planas1">[42]</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with MBL-low genotype also disclosed a cytokine profile in blood characterized by a predominance of anti-inflammatory over pro-inflammatory cytokines. Furthermore, the persistence of this anti-inflammatory profile at 3 months after stroke was in stronger support of a genetic trait rather than an acute-phase reaction. It can be argued that the improved functional recovery and increased brain tissue survival associated with a MBL-low genotype were related in part with a cytokine environment that allowed brain cells to be exposed to stronger anti-inflammatory signaling [42].
###end p 66
###begin p 67
###xml 370 374 370 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008433-Matzinger1">[43]</xref>
###xml 736 744 <span type="species:ncbi:9606">patients</span>
In summary, this study shows the major relevance of the MBL pathway of complement activation in acute ischemic or hemorrhagic stroke. Although the mechanisms that lead to ischemic and hemorrhagic stroke may differ, our results are in agreement with the concept of a danger model in which signals of cell injury sensed by immune receptors trigger shared immune responses [43]. Our data indicate that a genetically-defined MBL deficiency facilitates anti-inflammatory responses after acute stroke that result in long lasting beneficial effects on post-stroke functional recovery. Validation of these results would justify the quest of therapeutic interventions aimed to specifically inhibit the lectin pathway of complement activation in patients with acute stroke.
###end p 67
###begin title 68
Supporting Information
###end title 68
###begin p 69
Extended methods
###end p 69
###begin p 70
(0.04 MB DOC)
###end p 70
###begin p 71
Click here for additional data file.
###end p 71
###begin p 72
Complement system activation in carriers of D105>G and WT MASP2-genotypes. Serum concentration (g/L) of C3 and C4 at day 0 (d0) (n = 96) and day 2 (d2) (n = 96). Values are represented as meanA+/-SD.
###end p 72
###begin p 73
(2.05 MB TIF)
###end p 73
###begin p 74
Click here for additional data file.
###end p 74
###begin p 75
Balance between T helper (h) 1 cytokines and Th2 cytokines and clinical outcome. Serum measurements at day 0 (d0) (n = 129); day 1 (d1) (n = 121); day 2 (d2) (n = 122); day 3 (d3) (n = 116); day 4 (d4) (n = 111), day 7 (d7) (n = 101), and day 90 (d90) (n = 92). Values are mean A+/- SD. *p<0.05.
###end p 75
###begin p 76
(0.67 MB TIF)
###end p 76
###begin p 77
Click here for additional data file.
###end p 77
###begin p 78
###xml 15 23 <span type="species:ncbi:9606">patients</span>
Main traits in patients with ischemic or hemorrhagic stroke.
###end p 78
###begin p 79
(0.03 MB DOC)
###end p 79
###begin p 80
Click here for additional data file.
###end p 80
###begin p 81
We thank Ms. Belen Suarez for helpful technical assistance.
###end p 81
###begin title 82
References
###end title 82
###begin article-title 83
Innate autoimmunity.
###end article-title 83
###begin article-title 84
Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection.
###end article-title 84
###begin article-title 85
###xml 46 51 <span type="species:ncbi:9606">human</span>
Alterations in plasma complement levels after human ischemic stroke.
###end article-title 85
###begin article-title 86
###xml 92 95 <span type="species:ncbi:9606">man</span>
Complement activation in the central nervous system following blood-brain barrier damage in man.
###end article-title 86
###begin article-title 87
The role of complement in inflammation and phagocytosis.
###end article-title 87
###begin article-title 88
Complement component C3 mediates inflammatory injury following focal cerebral ischemia.
###end article-title 88
###begin article-title 89
The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q.
###end article-title 89
###begin article-title 90
Complement-dependent P-selectin expression and injury following ischemic stroke.
###end article-title 90
###begin article-title 91
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</sup>
Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein.
###end article-title 91
###begin article-title 92
###xml 79 83 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Complement activation contributes to hypoxic-ischemic brain injury in neonatal rats.
###end article-title 92
###begin article-title 93
###xml 58 64 <span type="species:ncbi:10090">murine</span>
C3a receptor modulation of granulocyte infiltration after murine focal cerebral ischemia is reperfusion dependent.
###end article-title 93
###begin article-title 94
Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury.
###end article-title 94
###begin article-title 95
Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q.
###end article-title 95
###begin article-title 96
The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury.
###end article-title 96
###begin article-title 97
Recombinant C1-inhibitor in Brain Ischemic Injury.
###end article-title 97
###begin article-title 98
The mannan-binding lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin pathway activation complex encoded by two genes.
###end article-title 98
###begin article-title 99
Mannose-binding lectin in innate immunity: past, present and future.
###end article-title 99
###begin article-title 100
C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells.
###end article-title 100
###begin article-title 101
Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein.
###end article-title 101
###begin article-title 102
Inherited deficiency of mannan-binding lectin-associated serine protease 2.
###end article-title 102
###begin article-title 103
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Mannose-binding Lectin in Immunity: Friend, Foe, or Both?
###end article-title 103
###begin article-title 104
###xml 74 78 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
Anti-VCAM-1 antibodies did not protect against ischemic damage neither in rats nor in mice.
###end article-title 104
###begin article-title 105
###xml 53 58 <span type="species:ncbi:10090">mouse</span>
Monofilament middle cerebral artery occlusion in the mouse.
###end article-title 105
###begin article-title 106
###xml 71 76 <span type="species:ncbi:9606">human</span>
Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin.
###end article-title 106
###begin article-title 107
###xml 67 72 <span type="species:ncbi:10090">mouse</span>
Mannan-binding lectin recognizes structures on ischemic reperfused mouse kidneys and is implicated in tissue injury.
###end article-title 107
###begin article-title 108
The Early Systemic Prophylaxis of Infection after Stroke study: a randomized clinical trial.
###end article-title 108
###begin article-title 109
Novel MASP2 variants detected among North African and Sub-Saharan individuals.
###end article-title 109
###begin article-title 110
Mannose-binding lectin: structure, function, genetics and disease associations.
###end article-title 110
###begin article-title 111
Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation.
###end article-title 111
###begin article-title 112
Assays for the functional activity of the mannan-binding lectin pathway of complement activation.
###end article-title 112
###begin article-title 113
Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals.
###end article-title 113
###begin article-title 114
Mannan-binding-lectin-associated serine proteases, characteristics and disease associations.
###end article-title 114
###begin article-title 115
###xml 41 46 <span type="species:ncbi:9606">human</span>
Systemic complement activation following human acute ischaemic stroke.
###end article-title 115
###begin article-title 116
Infection after acute ischemic stroke: a manifestation of brain-induced immunodepression.
###end article-title 116
###begin article-title 117
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 91 107 <span type="species:ncbi:562">Escherichia coli</span>
Bridging effects of recombinant human mannose-binding lectin in macrophage phagocytosis of Escherichia coli.
###end article-title 117
###begin article-title 118
###xml 26 31 <span type="species:ncbi:9606">human</span>
###xml 90 102 <span type="species:ncbi:89924">Cryptococcus</span>
###xml 90 113 <span type="species:ncbi:5207">Cryptococcus neoformans</span>
###xml 123 128 <span type="species:ncbi:9606">human</span>
Induction of TNF-alpha in human peripheral blood mononuclear cells by the mannoprotein of Cryptococcus neoformans involves human mannose binding protein.
###end article-title 118
###begin article-title 119
###xml 59 64 <span type="species:ncbi:9606">human</span>
Monocyte subtypes predict clinical course and prognosis in human stroke.
###end article-title 119
###begin article-title 120
###xml 90 95 <span type="species:ncbi:9606">human</span>
Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin.
###end article-title 120
###begin article-title 121
Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members.
###end article-title 121
###begin article-title 122
C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction.
###end article-title 122
###begin article-title 123
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 105 109 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats.
###end article-title 123
###begin article-title 124
Regulatory T cells protect the brain after stroke.
###end article-title 124
###begin article-title 125
The danger model: a renewed sense of self.
###end article-title 125
###begin p 126
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 126
###begin p 127
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Financed in part by the European Community (FP7/2007-2013; grant agreement ndegrees 201024), the Spanish Ministry of Education and Science (SAF2008-04515-CO2-01 to AMP), the non-profitable foundation 'Fundacion Melchor Colet' to A.Ch., and the Spanish Network for the Research in Infectious Diseases (REIPI, RD06/0008/1013) to F.L. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. A. Cervera and X. Urra are recipients of grants from the Spanish Institute of Health Carlos III.
###end p 127

